Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $50 Million

Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 18,181,818 ordinary shares at a public offering price of $2.75 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,727,272 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Nabriva Therapeutics.

The offering is expected to close on or about July 31, 2018, subject to customary closing conditions. Morgan Stanley is acting as sole book-running manager for the offering, Needham & Company, SunTrust Robinson Humphrey, and Wedbush PacGrow are acting as lead managers for the offering and Northland Capital Markets is acting as a manager for the offering.

The public offering is being made pursuant to a shelf registration statement, including a prospectus, on Form S-3 that was filed by Nabriva Therapeutics with the Securities and Exchange Commission (“SEC”) and was declared effective on April 27, 2018. A final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy Nabriva Therapeutics’ ordinary shares, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Offers will be made only by means of a prospectus supplement and the accompanying prospectus, forming a part of the registration statement.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections.

Die inhaltliche Verantwortung für diesen Beitrag liegt ausschließlich beim Aussender. Beiträge können Vorhersagen enthalten, die auf Erwartungen an zukünftige Ereignisse beruhen, die zur Zeit der Erstellung des Beitrags in Aussicht standen. Bitte verlassen Sie sich nicht auf diese zukunftsgerichteten Aussagen.

Als Life Sciences Organisation mit Sitz in Wien möchten Sie, dass LISAvienna auf Ihre News und Events hinweist? Senden Sie uns einfach Ihre Beiträge an news(at)